Effective Diagnosis of Prostate Cancer Based on mRNAs From Urinary Exosomes
Quick Facts
- Publication title: Effective Diagnosis of Prostate Cancer Based on mRNAs From Urinary Exosomes
- Journal: FRONT MED-LAUSANNE
- Year: 2022
- DOI: 10.3389/fmed.2022.736110
- PMID/PMCID: 35402423; PMC8983915
Research overview
Novel non-invasive biomarkers are urgently required to improve the diagnostic sensitivity and specificity of prostate cancer (PCa). These findings suggested that mRNAs from urinary exosomes have the potential in serving as novel and non-invasive indicators for PCa diagnosis and prediction.
Key findings
The expression of urinary exosomal ERG, PCA3, PSMA, CK19, and EpCAM were significantly increased in patients with PCa compared with healthy males.
Kaplan-Meier curves demonstrated that PCA3, ARV7, and EpCAM were associated in androgen-deprivation therapy (ADT) failure time which is defined as from the initiation of ADT in hormone-sensitive stage to the development of castration-resistant prostate cancer.
Study design
Exosomes were obtained using size-exclusion chromatography (SEC), out of which RNAs were extracted, then analyzed by quantitative reverse transcription-polymerase chain reaction according to manufacturer's protocol.
Echo Biotech Role
Echo Biotech contributed EV isolation and purification, qPCR validation; the study also used or cited Exosupur®.
Related platforms: Exoomics®, Research Reagents & Tools
Related services and capabilities: EV Isolation & Purification, qPCR Validation, Research Reagent / Product Supply
Related products or reagents: Exosupur® EV Isolation/Purification Kit
References
Original publication: Effective Diagnosis of Prostate Cancer Based on mRNAs From Urinary Exosomes Frontiers in Medicine. 2022. DOI: 10.3389/fmed.2022.736110. PMID/PMCID: 35402423; PMC8983915.